A study has demonstrated that Onco-Innovations' technology can effectively inhibit DNA repair in cancer cells, which may enhance the efficacy of radiation therapy.

VANCOUVER, BC / ACCESSWIRE / January 9, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is excited to share details about its exclusively licensed technology involving a novel class of PNKP (Polynucleotide Kinase 3'-Phosphatase) inhibitors (the "Technology"). Recent research[1] has demonstrated that this technology is effective in targeting and inhibiting DNA repair mechanisms in cancer cells. This advancement holds promise for enhancing cancer treatments and may lead to better outcomes for patients by increasing the vulnerability of cancer cells to radiation therapy.

The Technology centers around PNKP (Polynucleotide Kinase 3'-Phosphatase), an enzyme vital for the repair mechanisms of DNA damage in cancerous cells. By targeting and inhibiting PNKP, this Technology aims to hinder the ability of cancer cells to mend the damage inflicted by radiation therapy, which could lead to a more effective treatment outcome. This strategy holds promise not only for amplifying the therapeutic effects on tumors but also for decreasing the chances of cancer cell survival and recurrence.